John Higuchi Acquires 123,000 Shares of Lipocine (NASDAQ:LPCN) Stock

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi bought 123,000 shares of the company’s stock in a transaction that occurred on Monday, April 6th. The shares were acquired at an average cost of $2.05 per share, with a total value of $252,150.00. Following the transaction, the director owned 163,797 shares in the company, valued at approximately $335,783.85. This represents a 301.49% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Lipocine Stock Performance

LPCN opened at $2.00 on Wednesday. The firm has a 50 day moving average price of $7.93 and a 200 day moving average price of $5.77. The company has a market cap of $14.60 million, a PE ratio of -1.19 and a beta of 1.09. Lipocine Inc. has a 1 year low of $1.81 and a 1 year high of $12.37.

Lipocine (NASDAQ:LPCN) last posted its earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.26. The firm had revenue of $1.15 million during the quarter, compared to the consensus estimate of $0.12 million. Lipocine had a negative net margin of 487.00% and a negative return on equity of 59.30%.

Institutional Trading of Lipocine

Several large investors have recently bought and sold shares of the company. Ikarian Capital LLC acquired a new stake in Lipocine in the fourth quarter valued at approximately $1,602,000. Squadron Capital Management LLC acquired a new stake in shares of Lipocine during the fourth quarter worth approximately $4,256,000. Boothbay Fund Management LLC acquired a new stake in shares of Lipocine during the fourth quarter worth approximately $441,000. Diadema Partners LP acquired a new stake in shares of Lipocine during the fourth quarter worth approximately $2,095,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Lipocine during the fourth quarter worth approximately $567,000. Institutional investors and hedge funds own 9.11% of the company’s stock.

Lipocine News Summary

Here are the key news stories impacting Lipocine this week:

• Positive Sentiment: Company insiders increased stakes — CEO Mahesh Patel bought 25,000 shares (~$2.03 avg) and director John W. Higuchi bought 123,000 shares, signaling insider confidence and providing buy-side support to the stock. Mahesh Patel Purchases 25,000 Shares of Lipocine (NASDAQ:LPCN) Stock
• Neutral Sentiment: HC Wainwright updated models upward — the firm raised FY2026 and quarterly EPS forecasts (e.g., FY2026 to ($1.91) from ($2.27) and several quarter EPS revisions) but keeps a “Neutral” rating, an outcome that reduces downside in estimates but does not convert to an upgrade. MarketBeat summary of analyst estimates
• Neutral Sentiment: Recent quarterly results showed a revenue beat and narrower-than-expected EPS loss (reported ($0.34) vs consensus ($0.60)), which supports the revised analyst estimates but the company remains loss-making and small-cap volatility is high. MarketBeat financial summary
• Negative Sentiment: HC Wainwright appears to have reduced its stance in a separate report (MSN coverage) — any downgrade or more cautious wording from a specialist biotech/healthcare desk can prompt short-term selling in a low-float name like LPCN. HC Wainwright & Co. downgrades Lipocine (LPCN)
• Negative Sentiment: Shareholder litigation inquiry — Johnson Fistel announced an investigation into potential claims involving Lipocine executives; legal risk and potential costs can weigh on sentiment and valuation. Johnson Fistel investigation announcement

Analysts Set New Price Targets

Several analysts have issued reports on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Lipocine in a research report on Monday. Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lipocine in a research report on Friday, March 27th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $15.00.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.